VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Dixon on Systemic Advances in Breast Cancer

J. Michael Dixon, MD
Published: Tuesday, Sep 13, 2011

J. Michael Dixon, MBChB, MD, Professor of Surgery and Consultant Surgeon of the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland, describes all of the recent advances in breast cancer systemic therapy.

Dixon explains that in the hormonal systemic therapy there has been an advance in the treatment of postmenopausal women using aromatase inhibitors.

Chemotherapy and targeted agents have advanced considerably with the increased use of taxane drugs, anthracyclines, and anti-HER2 drugs such lapatinib and pertuzumab.
 
J. Michael Dixon, MBChB, MD, Professor of Surgery and Consultant Surgeon of the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland, describes all of the recent advances in breast cancer systemic therapy.

Dixon explains that in the hormonal systemic therapy there has been an advance in the treatment of postmenopausal women using aromatase inhibitors.

Chemotherapy and targeted agents have advanced considerably with the increased use of taxane drugs, anthracyclines, and anti-HER2 drugs such lapatinib and pertuzumab.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x